BIOGEN INC. - COMMON STOCK

TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union

24 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

09 Jun 2024 19:37:43 By Nasdaq GlobeNewswire

Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel

03 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

30 May 2024 16:51:04 By Nasdaq GlobeNewswire

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

22 May 2024 07:30:00 By Nasdaq GlobeNewswire

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

16 May 2024 07:30:14 By Nasdaq GlobeNewswire

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

14 May 2024 19:33:37 By Nasdaq GlobeNewswire

Biogen Reports Progress on Corporate Responsibility Priorities

02 May 2024 07:30:00 By Nasdaq GlobeNewswire

Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®

25 Apr 2024 16:05:00 By Nasdaq GlobeNewswire

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

06 Mar 2024 07:30:51 By Nasdaq GlobeNewswire

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

04 Mar 2024 16:15:57 By Nasdaq GlobeNewswire

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

23 Feb 2024 07:00:26 By Nasdaq GlobeNewswire

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

12 Feb 2024 16:06:00 By Nasdaq GlobeNewswire

Biogen to Realign Resources for Alzheimer's Disease Franchise

31 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission

19 Dec 2023 07:30:21 By Nasdaq GlobeNewswire

CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease

15 Dec 2023 09:05:25 By Nasdaq GlobeNewswire

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

14 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

Biogen Appoints Monish Patolawala to its Board of Directors

06 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer’s Disease (CTAD) Conference

25 Oct 2023 17:26:00 By Nasdaq GlobeNewswire

New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease

25 Oct 2023 10:51:00 By Nasdaq GlobeNewswire